Drugs / CTL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04193098 | Jun 2019 → Jun 2021 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04193098 ↗ |
| Modality | Cell therapy | “Autologous Cytotoxic T Lymphocyte (CTL) Cell Immunotherapy” NCT04193098 ↗ |
| Route | Intravenous | “CTL, 1x10\^9, intravenous infusion,d14” NCT04193098 ↗ |